Muscle-invasive bladder cancer (MIBC) represents 25% of newly diagnosed bladder cancer. MIBC is aggressive and requires timely management. The current standard of care is neoadjuvant chemotherapy followed by radical cystectomy, an approach that could result in significant morbidities. Modifications in the chemotherapy regimens, as well as in perioperative care and surgical approach, have resulted in better overall toxicity profile and faster recovery. However, bladder-preservation in carefully selected patients can lead to acceptable oncological outcomes and better quality of life. Optimization of bladder-preservation protocols and proper identification of patients who tolerate and respond to various treatment modalities will significantly impact patient survival in the coming future.
Trends in cancer. 2019 Jun 22 [Epub]
Rashed Ghandour, Nirmish Singla, Yair Lotan
Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9110, USA., Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9110, USA. Electronic address: .